US2006177523A1PendingUtilityA1
Administration of a thiol-based chemoprotectant compound
Est. expiryApr 26, 2020(expired)· nominal 20-yr term from priority
A61P 39/00A61P 35/00A61P 43/00A61K 9/08A61K 31/282A61K 31/198A61K 33/04A61K 9/0019A61K 38/063A61K 31/195A61K 31/661A61K 31/095A61K 33/243
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of administration of a thiol-based chemoprotectant agent including NAC (N-acetylcysteine) and STS (sodium thiosulfate) that markedly affects biodistribution and protects against injury from diagnostic or therapeutic intra-arterial procedures. A method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the head or neck and brain tumors. The thiol-based chemoprotectant agent is administered intra-arterially with rapid and first pass uptake in organs and tissues other than the liver.
Claims
exact text as granted — not AI-modified1 - 48 . (canceled)
49 . A method for treating or mitigating myelosuppression, comprising:
administering intraarterially a high-dose thiol based chemoprotectant agent.
50 . The method for treating or mitigating myelosuppression of claim 49 wherein the high-dose thiol based chemoprotectant agent is from about 400 mg/m 2 to about 1200 mg/m 2 per procedure.
51 . The method for treating or mitigating myelosuppression of claim 49 wherein the high-dose thiol based chemoprotectant agent is selected from at least one of the group consisting of N-acetyl cysteine (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, and Ethyol.
52 - 76 . (canceled)Join the waitlist — get patent alerts
Track US2006177523A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.